{"disease":{"id":"cml-chronic-phase","name":"cml chronic phase"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05367765","title":"A Real World Study of the Efficacy and Safety of Flumatinib Versus Imatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase","phase":"PHASE4","overall_status":"NOT_YET_RECRUITING","enrollment_count":2400,"lead_sponsor_name":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT05353205","title":"A Study of the Efficacy and Safety of Flumatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":200,"lead_sponsor_name":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT03459534","title":"A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":173,"lead_sponsor_name":"Il-Yang Pharm. Co., Ltd.","has_results":false},{"nct_id":"NCT03481868","title":"EPIgenetics and in Vivo Resistance of Chronic Myeloid Leukemia Stem Cells to Tyrosine Kinase Inhibitors","phase":"NA","overall_status":"RECRUITING","enrollment_count":160,"lead_sponsor_name":"University Hospital, Clermont-Ferrand","has_results":false},{"nct_id":"NCT05367700","title":"A Study of HS-10382 in Patients With Chronic Myeloid Leukemia.","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":108,"lead_sponsor_name":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT06530810","title":"Study of HS-10382 Combination in Patients With Chronic Myeloid Leukemia (CML)","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":100,"lead_sponsor_name":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT04883125","title":"Value of Using Pioglitazone in Chronic Myeloid Leukemia Treatment","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":90,"lead_sponsor_name":"Mansoura University","has_results":false},{"nct_id":"NCT06121765","title":"Metabolic Alternation and Clinicohematological Characteristic in Chronic Phase CML in Patient Treated With TKI","phase":"","overall_status":"UNKNOWN","enrollment_count":45,"lead_sponsor_name":"Assiut University","has_results":false},{"nct_id":"NCT03885830","title":"Precision Dosing of Tyrosine Kinase Inhibitors in CML Patients","phase":"","overall_status":"COMPLETED","enrollment_count":45,"lead_sponsor_name":"UNC Lineberger Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT03560752","title":"CMV-MVA Triplex Vaccination of Stem Cell Donors in Preventing CMV Viremia in Participants With Allogeneic Transplant","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":34,"lead_sponsor_name":"City of Hope Medical Center","has_results":true},{"nct_id":"NCT04666025","title":"SARS-CoV-2 Donor-Recipient Immunity Transfer","phase":"","overall_status":"COMPLETED","enrollment_count":26,"lead_sponsor_name":"City of Hope Medical Center","has_results":false},{"nct_id":"NCT02782403","title":"Axitinib and Bosutinib in Treating Patients With Chronic, Accelerated, or Blastic Phase Chronic Myeloid Leukemia","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":4,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT01131325","title":"Study of Nilotinib in Ph+ CML-CP Patients With Low Imatinib Trough Plasma Concentrations","phase":"PHASE4","overall_status":"TERMINATED","enrollment_count":3,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true}],"total":13},"guidelines":[],"source":"Drug Landscape verified database"}